Brain cancer entails a number of trials and it's clear that some of them will be more recognized than others. What many will agree on, though, is that these procedures are done over the course of time and for good reason as well. Details have to be looked into and I do not think that they can be easily picked up on over the course of a day. That being said, there is an extensive nature of work to connect to the usage of a substance referred to as ETS2101.
The Wall Street Journal posted an article in regards to the ETS2101 trial, which has entailed a number of patients affected with either primary or secondary brain cancer. Each of them was given a particular dose of ETS2101. This was done in order to see how well their bodies would take to it and if they would need larger or smaller amounts. The study will be done through 2014 as well, which means that organizations along the lines of Voices against Brain Cancer should bring their attention towards it.
Of course, you may stop and wonder what exactly ETS2101 is. The article spoke about it and it's been said that it a drug commonly utilized in order to treat patients with trauma. Thanks to pharmacology, though, it's been believed that this drug can actually prove useful for the sake of helping cancer patients, too. Two studies are being done, one with primary cancer patients and the other entailing secondary cancer patients. To say that there has been quite a bit of time invested here would be an understatement.
Back to the subject of the procedure, though, patients have been treated with gradually higher doses of the drug until a tolerated level has been found. The report said that fifteen patients have completed the study with doses relative to body waste and the results have been generally positive. They took to the ETS2101 drug well and tumors have not responded objectively to the drug in question. It's an instance of success that, in my opinion, can most likely lead to further results seen down the road.
These studies require time in order for them to be truly effective, as just about anyone will be able to agree with. In my mind, brain cancer stands as one of the most serious conditions and, as a result, deserves all of the attention that it can get. This has been the case for the ETS2101 trial and it's good to see that it will continue on through 2014. During that time, I can only hope that even greater results will be seen, which can then parlay into the future.
The Wall Street Journal posted an article in regards to the ETS2101 trial, which has entailed a number of patients affected with either primary or secondary brain cancer. Each of them was given a particular dose of ETS2101. This was done in order to see how well their bodies would take to it and if they would need larger or smaller amounts. The study will be done through 2014 as well, which means that organizations along the lines of Voices against Brain Cancer should bring their attention towards it.
Of course, you may stop and wonder what exactly ETS2101 is. The article spoke about it and it's been said that it a drug commonly utilized in order to treat patients with trauma. Thanks to pharmacology, though, it's been believed that this drug can actually prove useful for the sake of helping cancer patients, too. Two studies are being done, one with primary cancer patients and the other entailing secondary cancer patients. To say that there has been quite a bit of time invested here would be an understatement.
Back to the subject of the procedure, though, patients have been treated with gradually higher doses of the drug until a tolerated level has been found. The report said that fifteen patients have completed the study with doses relative to body waste and the results have been generally positive. They took to the ETS2101 drug well and tumors have not responded objectively to the drug in question. It's an instance of success that, in my opinion, can most likely lead to further results seen down the road.
These studies require time in order for them to be truly effective, as just about anyone will be able to agree with. In my mind, brain cancer stands as one of the most serious conditions and, as a result, deserves all of the attention that it can get. This has been the case for the ETS2101 trial and it's good to see that it will continue on through 2014. During that time, I can only hope that even greater results will be seen, which can then parlay into the future.
About the Author:
Visit Voices Against Brain Cancer if you're seeking some more information about glioblastoma and brain cancer awareness.
0 comments:
Post a Comment